The results of the STENO-2 study assessing the benefit of intensified therapy on risk of stroke.

Outpatient use at 90 days was seen for 5.9 and 3.0 percent of patients with and without inpatient use

Clinical characteristics, socioeconomic status, adverse effects do not predict adherence

~64 percent of children treated with Victoza achieved HbA1c levels less than 7 percent

Authors note lack of studies on whether extending sleep improves cardiometabolic health in adults

The American Diabetes Association 79th Scientific SessionsThe annual meeting of the American Diabetes Association was held from June 7 to 11 in San Francisco and attracted approximately 14,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in diabetes. The conference highlighted the latest advances …

When my wife was first diagnosed with diabetes we immediately started her on long acting insulin and the GLP-1 agonist Trulicity. I believe that the use of these 2 meds prolonged her insulin producing capacities for 3 years before the antibodies won out. This week we have a report from …

TrialNet research reveals the benefits of Teplizumab in delaying clinical type 1 diabetes in people at high risk.

The PREVIEW study examined which lifestyle interventions make a difference in preventing prediabetes from progressing to type 2.

RISE study data on improvements of beta-cell function in type 2 diabetes found response to treatment differs in adults vs youth.